Search
Pradaxa® (dabigatran etexilate) Overview Factsheet
bi-aff-act-eeo-stmts (2)
BI-TermsCondQualtrics.pdf
Breaking-Down-Biosimilars-Infographic.pdf
BIAH Corporate Booklet A5 Update
Glyxambi-LongForm.pdf
biah-us-overview-for-usda
BIPI Post Marketing Requirements PDF | Boehringer Ingelheim US
PAP Eligibility Information
Benefits Overview (BIPI)
Benefits Overview (BIUSA)
Paid time off Policy BIPI
BIFellowshipBrochure 24-26
BI_asthma_infographic.pdf
Biotherapeutics Modalities Infographic
bi-aff-act-eeo-stmts (2)
Research & Development Video | BI Careers
Prof. Eric Haaksma speaks about his career and the Boehringer Ingelheim mission to transform lives for generations.
Accessibility Statement
Accessibility Statement
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
BI Launches Bovikalc Dry for Dairy Cows | Boehringer Ingelheim US
Click here to read more on the launch of the new Bovikalc® Dry for Dairy Cows, an oral mineral supplement contributing to well-being for dairy cows.
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests